Perindopril + Amlodipine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Hypertension
Adult: Preparations available:
Perindopril arginine 3.5 mg and amlodipine 2.5 mg
Perindopril arginine 7 mg and amlodipine 5 mg
Perindopril arginine 14 mg and amlodipine 10 mg
Perindopril arginine 5 mg and amlodipine 5 mg
Perindopril arginine 5 mg and amlodipine 10 mg
Perindopril arginine 10 mg and amlodipine 5 mg
Perindopril arginine 10 mg and amlodipine 10 mg

Initially, 3.5/2.5 mg once daily. Adjust dosage according to BP goals w/ 7-14 days interval between titrations. Max: Perindopril arginine 14 mg and amlodipine 10 mg once daily.
Elderly: Initiate at 2.5 mg amlodipine component once daily.

Oral
Essential hypertension, Stable coronary artery disease
Adult: Preparations available:
Perindopril erbumine 4 mg and amlodipine 5 mg
Perindopril erbumine 8 mg and amlodipine 5 mg
Perindopril erbumine 4 mg and amlodipine 10 mg
Perindopril erbumine 8 mg and amlodipine 10 mg

As substitution therapy in patients already maintained w/ amlodipine and perindopril: One tab once daily, preferably in the morning.
Renal Impairment
Hypertension: Mild to moderate: Max: Perindopril arginine 7 mg and amlodipine 5 mg. Severe: Not recommended.
Cách dùng
Should be taken on an empty stomach.
Chống chỉ định
History of idiopathic angioedema. Severe hypotension, shock (e.g. cardiogenic shock), left ventricular outflow tract obstruction (e.g. high grade aortic stenosis), heart failure after acute MI. Pregnancy and lactation. Concomitant use w/ aliskiren esp in patients w/ DM or renal impairment (GFR <30 mL/min/1.73 m2).
Thận trọng
Patient w/ salt or volume depletion, severe obstructive coronary artery disease, renal artery and mitral and severe aortic stenosis, ischemic heart disease or cerebrovascular disease, hypertrophic cardiomyopathy w/ outflow tract obstruction, cardiac failure, collagen vascular disease. Hepatic and renal impairment. Elderly. Patient undergoing major surgery or during anaesthesia; desensitisation treatment (e.g. hymenoptera venom).
Phản ứng phụ
Significant: Angina/MI, hypotension, persistent nonproductive cough, acute renal failure, hyperkalaemia, cholestatic jaundice.
Nervous: Headache, dizziness, somnolence, paraesthesia, vertigo, fatigue, asthenia.
CV: Peripheral oedema, flushing, palpitations, bradycardia, chest pain, syncope, tachycardia, vasculitis.
GI: Abdominal pain, nausea, vomiting, dyspepsia, dysgeusia, diarrhoea, constipation.
Resp: Dyspnoea.
Haematologic: Agranulocytosis, thrombocytopenia, anaemia.
Musculoskeletal: Muscle cramps.
Ophthalmologic: Visual disturbances.
Dermatologic: Rash.
Others: Tinnitus.
Potentially Fatal: Hypersensitivity reactions (e.g. angioedema of the tongue, glottis and larynx), arrhythmia, prolonged systemic hypotension, shock. Rarely, fulminant hepatic necrosis.
Thông tin tư vấn bệnh nhân
This drug may cause occasional dizziness or weariness, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor BP, renal function, electrolytes (e.g. serum K level), CBC w/ differential. Assess cardiac status and fluid balance.
Tương tác
Increased hypotensive effects w/ antihypertensive agents (e.g. β-blockers), diuretics, and vasodilators. May increase serum levels and toxicity of lithium. May cause nitritoid reactions w/ Na aurothiomalate. Increased risk of angioneurotic oedema w/ estramustine. May increase hypoglycaemic effect w/ insulin or sulfonamides. Increased antihypertensive effect and risk of orthostatic hypotension w/ TCAs, antipsychotics, anaesthetics, α-blockers. May increase risk of angioedema w/ mammalian target of rapamycin (mTOR) inhibitors (e.g. sirolimus, everolimus, temsirolimus). May cause worsening of renal function and loss of antihypertensive effect w/ NSAIDs. Decreased antihypertensive effects w/ NSAIDs and sympathomimetics.
Amlodipine: Increased serum concentration of simvastatin. Increased antihypertensive effects w/ amifostine, baclofen. Increased serum concentration w/ CYP3A4 inhibitors (e.g. diltiazem). Decreased serum concentration w/ CYP3A4 inducers (e.g. anticonvulsant agents, rifampicin).
Perindopril: Increased risk of hyperkalaemia w/ K-sparing diuretics (e.g. amiloride, eplerenone, spironolactone, triamterene), K supplements or other agents which increases serum K level (e.g. NSAID, ciclosporin, heparin, indomethacin).
Potentially Fatal: May cause anaphylactoid reactions w/ dextran sulfate in LDL apheresis. May increase risk of hypotension, hyperkalaemia, and changes in renal function w/ aliskiren.
Food Interaction
Food may decrease rate of absorption.
Tác dụng
Description: Perindopril, a prodrug of perindoprilat, is an ACE inhibitor which prevents convertion of angiotensin I to angiotensin II, thereby increasing plasma renin activity and decreasing vasoconstriction and aldosterone secretion.
Amlodipine, a dihydropyridine Ca channel blocker, inhibits transmembrane influx of Ca ions into vascular smooth muscle and cardiac muscle thereby causing relaxation and vasodilation. It also directly acts on vascular smooth muscle causing reductions in peripheral vascular resistance and BP.
Pharmacokinetics:
Absorption: Perindopril: Rapidly absorbed from the GI tract. Effect of food: Slightly reduced absorption w/ food. Absolute bioavailability: Approx 65-75% (perindopril); approx 25% (perindoprilat). Time to peak plasma concentration: 1 hr; 3-4 hr (perindoprilat).
Amlodipine: Well absorbed. Absolute bioavailability: 64-80%. Time to peak plasma concentration: 6-12 hr.
Distribution: Perindopril: Volume of distribution: Approx 0.2 L/kg (perindoprilat). Plasma protein binding: 60% (perindopril); 10-20% (perindoprilat).
Amlodipine: Enters breast milk. Volume of distribution: Approx 21 L/kg. Plasma protein binding: Approx 98%.
Metabolism: Perindopril: Extensively metabolised in the liver via hydrolysis by hepatic esterases to perindoprilat (as active metabolite) and inactive metabolites including glucuronides.
Amlodipine: Extensively metabolised in the liver to inactive metabolites.
Excretion: Perindopril: Via urine (4-12% as unchanged drug). Elimination half-life: 25-30 hr or longer (perindoprilat).
Amlodipine: Via urine (60%, 10% as unchanged drug). Terminal elimination half-life: 30-50 hr.
Đặc tính

Chemical Structure Image
Perindopril

Source: National Center for Biotechnology Information. PubChem Database. Perindopril, CID=107807, https://pubchem.ncbi.nlm.nih.gov/compound/Perindopril (accessed on Jan. 22, 2020)


Chemical Structure Image
Amlodipine

Source: National Center for Biotechnology Information. PubChem Database. Amlodipine, CID=2162, https://pubchem.ncbi.nlm.nih.gov/compound/Amlodipine (accessed on Jan. 20, 2020)

Bảo quản
Store below 25°C. Protect from light and moisture.
Phân loại ATC
C09BB04 - perindopril and amlodipine ; Belongs to the class of ACE inhibitors and calcium channel blockers. Used in the treatment of cardiovascular diseases.
References
Anon. Perindopril and Amlodipine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/08/2017.

Buckingham R (ed). Amlodipine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2017.

Buckingham R (ed). Perindopril. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/08/2017.

Prestalia (Symplmed Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/08/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Perindopril + Amlodipine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in